| DIRECT COMPETITOR COMPARISON | |
| ARQL | ARIA | ARRY | OSIP | Industry | | Market Cap: | 154.17M | 239.71M | 89.74M | 1.92B | 161.24M | | Employees: | 107 | 150 | 348 | 491 | 95 | | Qtrly Rev Growth (yoy): | 141.60% | 40.30% | 37.30% | 17.80% | 20.50% | | Revenue (ttm): | 23.28M | 8.75M | 27.12M | 402.62M | 46.74M | | Gross Margin (ttm): | -96.61% | N/A | 24.83% | 97.76% | 68.58% | | EBITDA (ttm): | -34.24M | -66.87M | -87.72M | 146.47M | -7.12M | | Oper Margins (ttm): | -154.58% | -811.94% | -346.62% | 34.98% | 2.25% | | Net Income (ttm): | -35.90M | -78.78M | -118.93M | 423.35M | N/A | | EPS (ttm): | -0.814 | -0.940 | -2.479 | 6.486 | -0.17 | | P/E (ttm): | N/A | N/A | N/A | 5.10 | 17.12 | | PEG (5 yr expected): | N/A | N/A | N/A | 1.83 | 1.04 | | P/S (ttm): | 6.83 | 28.52 | 3.47 | 4.76 | 4.17 |
|
| ARIA = Ariad Pharmaceuticals Inc. | | ARRY = Array BioPharma, Inc. | | OSIP = OSI Pharmaceuticals Inc. | | Industry = Drug Manufacturers - Other | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | OSIP | | Less Toxic Monoclonal Antibodies And Increased Patent Protection For Biologics Creates Multiple Positive Investment Scenarios In Biotechnology Sector
Sat 10:23am -
Wall Street Transcript | | • | ARRY | | Array BioPharma to Present at the Piper Jaffray Healthcare Conference
Mon, Nov 23 -
Business Wire | | • | ARIA | | Become a Recessionista? Not in This Stock Market
Mon, Nov 23 -
TradingMarkets.com | | • | ARIA | | ARIAD to Present Data on Pan-BCR-ABL Inhibitor AP24534 at 51st American Society of Hematology Meeting
Mon, Nov 23 -
Business Wire | | • | OSIP | | OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 3rd
Thu, Nov 19 -
Business Wire | | • | OSIP | | OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Mon, Nov 16 -
Business Wire | | • | ARIA | | ARIAD PHARMACEUTICALS INC Financials
Fri, Nov 13 -
EDGAR Online Financials | | • | OSIP | | Healthcare Guru Adds Selected Biotech, Pharma Stakes
Wed, Nov 11 -
Indie Research | | • | OSIP | | OSI PHARMACEUTICALS INC Financials
Wed, Nov 11 -
EDGAR Online Financials | | • | ARIA | | Bristol Licenses Arthritis Drug: BioBuzz
Tue, Nov 10 -
at TheStreet.com | | • | ARIA | | ARIAD to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
Tue, Nov 10 -
Business Wire | | • | ARRY | | ARRAY BIOPHARMA INC Financials
Fri, Nov 6 -
EDGAR Online Financials | | • | ARRY | | HEADLINE STOCKS-U.S. small/midcap stocks on the move on Nov 5
Thu, Nov 5 -
at Reuters | | • | ARRY | | Array Biopharma upgraded by UBS
Thu, Nov 5 -
Briefing.com | | • | ARRY | | ARRAY BIOPHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal
Tue, Nov 3 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
